Page last updated: 2024-11-08

alanine and HIV

alanine has been researched along with HIV in 19 studies

Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.

HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.

Research Excerpts

ExcerptRelevanceReference
"Tenofovir alafenamide (TAF), a prodrug of tenofovir (TFV), is included in the majority of the recommended first-line antiretroviral regimens for patients living with human immunodeficiency virus (HIV), but there are limited data on TAF use in pregnant women."8.12Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network. ( Alba Alejandre, I; Bukkems, VE; Burger, D; Colbers, A; Garcia, C; Hidalgo Tenorio, C; Konopnicki, D; Lambert, JS; Necsoi, C; Richel, O; Te Brake, LHM; van der Meulen, E; van Hulzen, A; Weiss, F, 2022)
"A fixed-dose combination consisting of darunavir (Drv), cobicistat (Cobi), emtricitabine (2',3'-dideoxy-5-fluoro-3'-thiacytidine [FTC]), and tenofovir alafenamide (Taf) has been recently approved by the European Medicines Agency for the treatment of HIV infection, and is the first ever protease-inhibitor-based single-tablet regimen."4.98Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. ( Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N, 2018)
"Tenofovir alafenamide (TAF), a prodrug of tenofovir (TFV), is included in the majority of the recommended first-line antiretroviral regimens for patients living with human immunodeficiency virus (HIV), but there are limited data on TAF use in pregnant women."4.12Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network. ( Alba Alejandre, I; Bukkems, VE; Burger, D; Colbers, A; Garcia, C; Hidalgo Tenorio, C; Konopnicki, D; Lambert, JS; Necsoi, C; Richel, O; Te Brake, LHM; van der Meulen, E; van Hulzen, A; Weiss, F, 2022)
" Efficacy against vaginal simian-HIV (SHIV) infection was investigated in six pigtailed macaques that received two tenofovir alafenamide implants (0."4.12Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model. ( Dobard, C; García-Lerma, JG; Gary, J; Gatto, G; Heneine, W; Holder, A; Johnson, L; Khalil, G; Krovi, A; Li, L; Luecke, E; Massud, I; Mills, P; Mitchell, J; Nishiura, K; Pan, Y; Ruone, S; van der Straten, A, 2022)
" We used a macaque model of repeated exposures to simian human immunodeficiency virus (SHIV) to investigate whether TAF alone or the combination of TAF and emtricitabine (FTC) can prevent vaginal infection."3.91Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques. ( Babusis, D; Callebaut, C; Cong, ME; Deyounks, F; Dinh, C; García-Lerma, JG; Heneine, W; Holder, A; Johnson, R; Khalil, G; Lipscomb, J; Massud, I; McCallister, S; Nishiura, K; Pan, Y; Park, Y; Rooney, JF; Ruone, S, 2019)
" Population pharmacokinetic models were developed using measured intracellular metabolite, endogenous nucleotide competitors, and extracellular parent drug concentrations."1.48A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs. ( Chen, J; Cottrell, ML; Dumond, JB; Garrett, KL; Maas, BM; Prince, HA; Schauer, AP; Sykes, C; White, N, 2018)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19901 (5.26)18.7374
1990's2 (10.53)18.2507
2000's5 (26.32)29.6817
2010's4 (21.05)24.3611
2020's7 (36.84)2.80

Authors

AuthorsStudies
Roa, PE1
Bazzi, R1
Bukkems, VE1
Necsoi, C1
Hidalgo Tenorio, C1
Garcia, C1
Alba Alejandre, I1
Weiss, F1
Lambert, JS1
van Hulzen, A1
Richel, O1
Te Brake, LHM1
van der Meulen, E1
Burger, D1
Konopnicki, D1
Colbers, A1
De Clercq, E2
Ma, J1
Nance, RM1
Delaney, JAC1
Whitney, BM1
Bamford, L1
Gravett, RM1
Moore, RD1
Napravnik, S1
Mayer, KH1
Jacobson, JM1
Christopoulos, K1
Burkholder, GA1
Keruly, J1
Eron, JJ1
Martin, J1
Cachay, ER1
Saag, MS1
Crane, HM1
Kitahata, MM1
Massud, I2
Krovi, A1
Nishiura, K2
Ruone, S2
Li, L1
Holder, A2
Gary, J1
Mills, P1
Mitchell, J1
Khalil, G2
Pan, Y2
Luecke, E1
Gatto, G1
Heneine, W2
García-Lerma, JG2
Johnson, L1
van der Straten, A1
Dobard, C1
Liu, W1
Yu, S1
Yan, B1
Ma, R1
Zhang, Q1
Zhang, YS1
Xu, B1
Tong, ZW1
Zhao, CS1
Zhao, RG1
Garrett, KL1
Chen, J1
Maas, BM1
Cottrell, ML1
Prince, HA1
Sykes, C1
Schauer, AP1
White, N1
Dumond, JB1
Squillace, N1
Bozzi, G1
Colella, E1
Gori, A1
Bandera, A1
Cong, ME1
Dinh, C1
Lipscomb, J1
Johnson, R1
Deyounks, F1
Rooney, JF1
Babusis, D1
Park, Y1
McCallister, S1
Callebaut, C1
Okamoto, Y1
Bernstein, JD1
Shikano, S1
Stanley, BJ1
Ehrlich, ES1
Short, L1
Yu, Y1
Xiao, Z1
Yu, XF1
Xiong, Y1
del Alamo, M1
Neira, JL1
Mateu, MG1
Haugaard, SB1
Andersen, O1
Dela, F1
Holst, JJ1
Storgaard, H1
Fenger, M1
Iversen, J1
Madsbad, S1
Ma, X1
Zheng, W1
Wei, D1
Ma, Y1
Wang, T1
Wang, J1
Liu, Q1
Yang, S1
Fossey, C1
Huynh, NT1
Vu, AH1
Vidu, A1
Zarafu, I1
Laduree, D1
Schmidt, S1
Laumond, G1
Aubertin, AM1
Balzarini, J1
Kruining, J1
Wedgwood, O1
Pannecouque, C1
Aquaro, S1
Perno, CF1
Naesens, L1
Witvrouw, M1
Heijtink, R1
McGuigan, C1
Ashkenazi, A1
Presta, LG1
Marsters, SA1
Camerato, TR1
Rosenthal, KA1
Fendly, BM1
Capon, DJ1
Ahluwalia, G1
Cooney, DA1
Mitsuya, H1
Fridland, A1
Flora, KP1
Hao, Z1
Dalal, M1
Broder, S1
Johns, DG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients on Highly Active Antiretroviral Therapy (HAART)[NCT00119769]Phase 446 participants (Actual)Interventional2005-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for alanine and HIV

ArticleYear
Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections.
    Viruses, 2021, 12-02, Volume: 13, Issue:12

    Topics: Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Dr

2021
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
    Drug design, development and therapy, 2018, Volume: 12

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV

2018

Other Studies

17 other studies available for alanine and HIV

ArticleYear
Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with pancreatic cancer.
    International journal of STD & AIDS, 2022, Volume: 33, Issue:1

    Topics: Adenine; Aged; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV;

2022
Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4

    Topics: Adenine; Alanine; Anti-HIV Agents; Female; HIV; HIV Infections; Humans; Pregnancy; Pregnant Women; T

2022
Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine;

2022
Safety and efficacy of a biodegradable implant releasing tenofovir alafenamide for vaginal protection in a macaque model.
    The Journal of antimicrobial chemotherapy, 2022, 10-28, Volume: 77, Issue:11

    Topics: Absorbable Implants; Alanine; Animals; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections;

2022
Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.
    Biochemical pharmacology, 2022, Volume: 204

    Topics: Adenine; Alanine; Alcohol Drinking; Anti-HIV Agents; Carboxylic Ester Hydrolases; Chromatography, Li

2022
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
    Chinese medical journal, 2020, Dec-05, Volume: 133, Issue:23

    Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections

2020
A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
    The Journal of pharmacology and experimental therapeutics, 2018, Volume: 367, Issue:2

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; HIV; HIV Infections; Humans; Middle

2018
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
    The Journal of infectious diseases, 2019, 10-22, Volume: 220, Issue:11

    Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Disease Transmi

2019
Role of C-terminal membrane-proximal basic residues in cell surface trafficking of HIV coreceptor GPR15 protein.
    The Journal of biological chemistry, 2013, Mar-29, Volume: 288, Issue:13

    Topics: Alanine; Amino Acid Sequence; Cell Membrane; Endoplasmic Reticulum; Flow Cytometry; Golgi Apparatus;

2013
Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly.
    Journal of virology, 2008, Volume: 82, Issue:17

    Topics: Alanine; Amino Acid Sequence; Amino Acid Substitution; Cell Line; Consensus Sequence; Conserved Sequ

2008
Thermodynamic dissection of a low affinity protein-protein interface involved in human immunodeficiency virus assembly.
    The Journal of biological chemistry, 2003, Jul-25, Volume: 278, Issue:30

    Topics: Alanine; Capsid Proteins; Chromatography, Gel; Circular Dichroism; Dimerization; Dose-Response Relat

2003
Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells.
    European journal of endocrinology, 2005, Volume: 152, Issue:1

    Topics: Adult; Alanine; Antiretroviral Therapy, Highly Active; Blood Glucose; Body Composition; Cholesterol,

2005
Construction, expression, and purification of HIV-TAT-survivin (T34A) mutant: a pro-apoptosis protein in Escherichia coli.
    Protein expression and purification, 2006, Volume: 47, Issue:1

    Topics: Alanine; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; Cell Line, Tumor; Escherichia coli

2006
Synthesis and anti-HIV evaluation of hybrid-type prodrugs conjugating HIV integrase inhibitors with d4t by self-cleavable spacers containing an amino acid residue.
    Journal of enzyme inhibition and medicinal chemistry, 2007, Volume: 22, Issue:5

    Topics: Alanine; Anti-HIV Agents; Cells, Cultured; Dimerization; HIV; HIV Integrase Inhibitors; Inhibitory C

2007
Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus.
    FEBS letters, 1997, Jun-30, Volume: 410, Issue:2-3

    Topics: Adenosine Monophosphate; Alanine; Animals; Anti-HIV Agents; Antiviral Agents; Cell Line; Cells, Cult

1997
Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis.
    Proceedings of the National Academy of Sciences of the United States of America, 1990, Volume: 87, Issue:18

    Topics: Alanine; Amino Acid Sequence; Antibodies, Monoclonal; Binding Sites; CD4 Antigens; Cell Line; Comput

1990
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity.
    Biochemical pharmacology, 1987, Nov-15, Volume: 36, Issue:22

    Topics: Alanine; Animals; Cell Line; Chromatography, High Pressure Liquid; Deoxyadenine Nucleotides; Deoxyri

1987